Cohesic Inc

🔬 Advances in imaging are transforming cardiac amyloidosis care. Multimodality imaging enables earlier diagnosis, tracks treatment response, and may soon leverage AI for even greater precision. Learn more in this new paper: 📄https://loom.ly/e1Gx0y0 #CardiacAmyloidosis #openaccess #CVimaging

A new #JACC: Cardiovascular Imaging review explores how #CVimaging can aid diagnosis, track disease progression, and guide treatment decisions in AL and ATTR #Amyloidosis over the next decade. 🔍 Key modalities discussed: ✅ Speckle-tracking echocardiography (LV strain) ✅ Cardiac MRI (ECV mapping) ✅ SPECT/SPECT-CT (bone-avid tracers) ✅ PET scanning Patients prefer imaging over biopsies, and researchers are working to improve early detection and treatment monitoring. Standardization is a key challenge, but efforts are underway to validate imaging for use in clinical trials—including discussions on its role as a regulatory endpoint. 📖 Read the expert summary here: https://loom.ly/0NQ9vo0

Risk-enhancing factors (REFs) – clinical conditions, biomarker levels, and demographic factors – support clinical decision-making by refining CV risk assessment ❤️. This low-cost, high-yield approach 💡 is especially valuable for patients at intermediate risk. As research evolves, future guidelines may place greater emphasis on REFs. Stay up to date about REFs here! https://loom.ly/2gpfCsE #PatientCenteredCare #CardioResearch #CVRisk #ClinicalDecisionMaking

📢 This new study shows that AI-driven 4D modeling of multiphase CTA provides strong prognostic value for the prediction of outcomes after TAVR. By leveraging #4Dphenomics, researchers identified a strain threshold linked to a 2.7x higher risk of heart failure hospitalization or death. 🔍 Could this reshape preprocedural planning? Read more: https://loom.ly/9P0Wins #Cardiology #TAVR #CVimaging #CardiacCTA

GLP-1 receptor agonists like semaglutide & tirzepatide aren’t just for metabolic health—they’re showing real promise in improving symptoms, quality of life, and even heart structure in HFpEF! 🫀✨ Patients treated with these therapies show significant improvements in KCCQ scores, reflecting reduced symptoms and better overall quality of life—a major win for those managing HFpEF. . With obesity now recognized as a key driver of HFpEF, targeting weight loss is emerging as a game-changing approach to treatment. 🚀 🔗 Read more here! https://loom.ly/y5ZoCMw #Cardiology #HeartFailure

🎙️ New JCCT podcast! Host Cristina Fuss, MD, PhD, FSCCT is joined by experts Ed Nicol, Ahmad Slim & Jonathon Leipsic to explore the business of cardiac CT — from practice models to training innovations and data-driven growth. 📲 Click the link to listen and learn how to build and grow a successful cardiac CT program! https://loom.ly/FAV1VzI #CardiacCT #JCCT #CVimaging

Can 3 questions improve heart failure outcomes? This NEJM Catalyst article says yes. By asking individuals with heart failure (HF) to define a “good life,” the LACE program helps them set personal goals, build on strengths, and engage their support networks. Delivered by a multidisciplinary team in partnership with community health and social care agencies, the program’s 2020-2023 pilot showed: ✅ 58% fewer unplanned admissions ✅ 70% fewer inpatient days ✅ Shorter stays (7.1 to 5 days) ✅ Better quality of life (+0.19 EQ-5D score) ✅ Higher self-rated health (+9 points EQ-5D VAS) Though focused on heart failure, the model shows promise for scaling to other conditions. Link to the article, including the 3 questions asked, is here: https://loom.ly/m5k_VSE #PatientCenteredCare #PatientReportedOutcomes #CardioResearch

INOVAIT has released "Data Mobilization", a framework to guide the safe and ethical sharing of Canadian health data to support innovation, economic growth, and better patient care. The principles emphasize transparency, ethics, patient input, governance, and Indigenous data sovereignty, fostering trust and responsible partnerships between healthcare and industry. This is an important initiative to help Canadian innovators drive the creation of AI-powered healthcare technologies. Learn more here: 🔗 https://loom.ly/GWIZCHM #AIDrivenHealthcare #AIinHealthcare #HealthData #CanadianHealthCare #MedicalInnovation #ResponsibleAI

🌍 A global task force has set a new standard for outcome reporting in heart valve disease (HVD), shifting from procedure-based to patient-centered measurement across all treatments. With 16 key measures—including PROs and cardiac function—this is a step toward more personalized care. Find the details here: https://loom.ly/2AHinXo #HeartValveDisease #OutcomeMeasurement #GlobalHealth

Recent advances in targeted therapies have renewed interest in HCM trials, yet challenges remain in this complex patient population. Identifying clinically and statistically meaningful endpoints is critical, with growing recognition of patient-reported outcomes 🗣️ like the KCCQ, alongside functional 📊 and biomarker-based 🧪 measures. Explore the latest insights here: https://loom.ly/IOuGOuQ #HypertrophicCardiomyopathy #HCM #CardioResearch #PatientReportedOutcomes #PatientCenteredCare